A Novel Pathological Prognostic Score (PPS) to Identify "Very High-Risk" Patients: a Multicenter Retrospective Analysis of 506 Patients with High Risk Gastrointestinal Stromal Tumor (GIST)

被引:12
作者
Liu, Xuechao [1 ,2 ,3 ]
Qiu, Haibo [1 ,2 ,3 ]
Wu, Zhiming [1 ,2 ,4 ]
Zhang, Peng [5 ]
Feng, Xingyu [6 ]
Chen, Tao [7 ]
Li, Yong [6 ]
Tao, Kaixiong [5 ]
Li, Guoxin [7 ]
Sun, Xiaowei [1 ,2 ,3 ]
Zhou, Zhiwei [1 ,2 ,3 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou 510060, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Canc Ctr, Dept Gastr Surg, 651 East Dongfeng Rd, Guangzhou 510060, Guangdong, Peoples R China
[4] Sun Yat Sen Univ, Canc Ctr, Dept Urol, Guangzhou, Guangdong, Peoples R China
[5] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gen Surg, Wuhan, Hubei, Peoples R China
[6] Guangdong Gen Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
[7] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China
基金
美国国家科学基金会;
关键词
Gastrointestinal stromal tumor; Pathological prognostic score; Ki-67 labeling index; Mitotic index; Prognosis; ADJUVANT IMATINIB MESYLATE; KI-67; THERAPY; KIT; MANAGEMENT; MUTATIONS; DIAGNOSIS; SURVIVAL; IMPACT; TRIAL;
D O I
10.1007/s11605-018-3799-5
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background To determine the better risk stratification based on surgical pathology and to assess the clinical outcomes after curative resection with a new scoring system in high risk gastrointestinal stromal tumor (GIST) patients. Methods We retrospectively evaluated 506 high-risk GIST patients who underwent curative resection as initial treatment at four centers from 2001 to 2015. Results Multivariate analysis revealed that only Ki-67 labeling index (LI) and mitotic index were independent prognostic factors of overall survival (OS). For the two tumor-related pathological factors, Ki-67 LI > 7% and mitotic index >= 7/50 high power fields were allocated 1 point each. The total score was defined as the Pathological Prognostic Score (PPS). When Ki-67 LI and mitotic index were replaced by PPS, a multivariate analysis still identified PPS as an independent predictor of OS (HR 2.719; 95% CI 1.309-5.650; P = 0.007). Patients with a PPS of 0, 1, or 2 had a 5-year survival of 91.8, 79.8, and 51.0%, respectively (P = 0.001). Furthermore, an elevated PPS (PPS = 2) was associated with larger tumor size, non-stomach tumor, and open resection (all P < 0.05). Conclusion The PPS independently predicted postoperative survival in high-risk GIST, and it might facilitate the selection of appropriate treatment strategy for these patients.
引用
收藏
页码:2150 / 2157
页数:8
相关论文
共 35 条
[1]   Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors [J].
Belev, Borislav ;
Brcic, Iva ;
Prejac, Juraj ;
Golubic, Zrna Antunac ;
Vrbanec, Damir ;
Bozikov, Jadranka ;
Aleric, Ivan ;
Boban, Marko ;
Razumovic, Jasminka Jakic .
WORLD JOURNAL OF GASTROENTEROLOGY, 2013, 19 (04) :523-527
[2]   Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 [J].
Blanke, Charles D. ;
Rankin, Cathryn ;
Demetri, George D. ;
Ryan, Christopher W. ;
von Mehren, Margaret ;
Benjamin, Robert S. ;
Raymond, A. Kevin ;
Bramwell, Vivien H. C. ;
Baker, Laurence H. ;
Maki, Robert G. ;
Tanaka, Michael ;
Hecht, J. Randolph ;
Heinrich, Michael C. ;
Fletcher, Christopher D. M. ;
Crowley, John J. ;
Borden, Ernest C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :626-632
[3]   Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels [J].
Casali, Paolo G. ;
Zalcberg, John ;
Le Cesne, Axel ;
Reichardt, Peter ;
Blay, Jean-Yves ;
Lindner, Lars H. ;
Judson, Ian R. ;
Schoffski, Patrick ;
Leyvraz, Serge ;
Italiano, Antoine ;
Grunwald, Viktor ;
Pousa, Antonio Lopez ;
Kotasek, Dusan ;
Sleijfer, Stefan ;
Kerst, Jan M. ;
Rutkowski, Piotr ;
Fumagalli, Elena ;
Hogendoorn, Pancras ;
Litiere, Saskia ;
Marreaud, Sandrine ;
van der Graaf, Winette ;
Gronchi, Alessandro ;
Verweij, Jaap .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (15) :1713-+
[4]   Imatinib mesylate - In the treatment of gastrointestinal stromal tumours [J].
Croom, KF ;
Perry, CM .
DRUGS, 2003, 63 (05) :513-522
[5]   Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour [J].
D'Ambrosio, Lorenzo ;
Palesandro, Erica ;
Boccone, Paola ;
Tolomeo, Francesco ;
Miano, Sara ;
Galizia, Danilo ;
Manca, Antonio ;
Chiara, Gabriele ;
Bertotto, Ilaria ;
Russo, Filippo ;
Campanella, Delia ;
Venesio, Tiziana ;
Sangiolo, Dario ;
Pignochino, Ymera ;
Siatis, Dimitrios ;
De Simone, Michele ;
Ferrero, Alessandro ;
Pisacane, Alberto ;
Tos, Angelo Paolo Dei ;
Aliberti, Sandra ;
Aglietta, Massimo ;
Grignani, Giovanni .
EUROPEAN JOURNAL OF CANCER, 2017, 78 :122-132
[6]   Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial [J].
DeMatteo, Ronald P. ;
Ballman, Karla V. ;
Antonescu, Cristina R. ;
Maki, Robert G. ;
Pisters, Peter W. T. ;
Demetri, George D. ;
Blackstein, Martin E. ;
Blanke, Charles D. ;
von Mehren, Margaret ;
Brennan, Murray F. ;
Patel, Shreyaskumar ;
McCarter, Martin D. ;
Polikoff, Jonathan A. ;
Tan, Benjamin R. ;
Owzar, Kouros .
LANCET, 2009, 373 (9669) :1097-1104
[7]  
Demetri GD, 2010, J NATL COMPR CANC NE, V8, pS1
[8]   Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors [J].
Eisenberg, Burton L. ;
Trent, Jonathan C. .
INTERNATIONAL JOURNAL OF CANCER, 2011, 129 (11) :2533-2542
[9]   Diagnosis of gastrointestinal stromal tumors: A consensus approach [J].
Fletcher, CDM ;
Berman, JJ ;
Corless, C ;
Gorstein, F ;
Lasota, J ;
Longley, BJ ;
Miettinen, M ;
O'Leary, TJ ;
Remotti, H ;
Rubin, BP ;
Shmookler, B ;
Sobin, LH ;
Weiss, SW .
HUMAN PATHOLOGY, 2002, 33 (05) :459-465
[10]   Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell renal cell carcinoma [J].
Gayed, Bishoy A. ;
Youssef, Ramy F. ;
Bagrodia, Aditya ;
Darwish, Oussama M. ;
Kapur, Payal ;
Sagalowsky, Arthur ;
Lotan, Yair ;
Margulis, Vitaly .
BJU INTERNATIONAL, 2014, 113 (04) :668-673